Table 2 Comparisons of medication and withdrawal of biologics between D2T and non-D2T groups in KOBIO registry
Variable | Total (n = 2,321) | D2T (n = 271) | Non-D2T (n = 2,050) | p-value |
|---|---|---|---|---|
Medication | ||||
 Previous treatments, N (%) | ||||
  Prior use of methotrexate | 2,175 (93.7) | 232 (85.6) | 1,943 (94.8) | < 0.001 |
  Prior use of sulfasalazine | 889 (38.3) | 79 (29.2) | 810 (39.5) | 0.001 |
  Prior use of leflunomide | 1,212 (52.2) | 118 (43.5) | 1,094 (53.4) | 0.002 |
 Concomitant treatments, N (%) | ||||
  Methotrexate | 1,885 (81.2) | 200 (73.8) | 1,685 (82.2) | 0.001 |
  Sulfasalazine | 308 (13.3) | 21 (7.8) | 287 (14.0) | 0.004 |
  Leflunomide | 597 (25.7) | 33 (12.2) | 564 (27.5) | < 0.001 |
  Corticosteroid use | 1,975 (85.1) | 229 (84.5) | 1,746 (85.2) | 0.757 |
  Corticosteroid dosagea, mg/day, mean (SD) | 5.4 (3.1) | 5.7 (3.3) | 5.4 (3.1) | 0.101 |
 Prior use of biologic agents, N (%) |  |  |  | < .0001 |
  0 | 1,686 (72.6) | 0 (0.0) | 1,686 (82.2) |  |
  1 | 362 (15.6) | 0 (0.0) | 362(17.7) |  |
  ≥ 2 | 273 (11.8) | 271 (100.0) | 2 (0.1) |  |
 Number of prior biologic agents, median [IQR] | 0 [0,1] | 2 [2, 3] | 0 [0,0] | < 0.001 |
 Current bDMARDs or tsDMARDs type, N (%) |  |  |  | < 0.001 |
  TNF inhibitors | 1,064 (45.9) | 53 (19.6) | 1,011 (49.3) |  |
   Etanercept | 314 (29.5) | 10 (18.9) | 304 (30.1) |  |
   Infliximab (remsima + remicade) | 210 (19.7) | 10 (18.9) | 200 (19.8) |  |
   Adalimumab | 379 (35.6) | 16 (30.2) | 363 (35.9) |  |
   Golimumab | 161 (15.1) | 17 (32.1) | 144 (14.2) |  |
  Rituximab | 27 (1.2) | 19 (7.0) | 8 (0.4) |  |
  Abatacept | 305 (13.2) | 37 (13.7) | 268 (13.1) |  |
  Tocilizumab | 562 (24.2) | 91 (33.7) | 471 (23) |  |
  JAK inhibitors | 362 (15.6) | 70 (25.9) | 292 (14.2) |  |
   Tofacitinib | 206 (56.9) | 50 (71.4) | 156 (53.4) |  |
   Baricitinib | 136 (37.6) | 17 (24.3) | 119 (40.8) |  |
   Upadacitinib | 20 (5.5) | 3 (4.3) | 17 (5.8) |  |
Withdrawal | ||||
 Treatment duration, years, median [IQR] | 3.74 [1.98, 5.48] | 3.67 [1.91, 5.21] | 3.76 [1.99, 5.53] | 0.257 |
 Withdrawal, N (%) | 1,025 (44.2) | 122 (45) | 903 (44.1) | 0.763 |
  Discontinuation, N (%) | 594 (25.6) | 63 (23.3) | 531 (25.9) | 0.347 |
  Switching, N (%) | 591 (25.5) | 85 (31.4) | 506 (24.7) | 0.018 |
 Withdrawal reason | ||||
  Clinical remission, N (%) | 74 (7.2) | 14 (11.5) | 60 (6.6) | 0.053 |
  Inefficacy, N (%) | 445 (43.4) | 71 (58.2) | 374 (41.4) | < 0.001 |
  Adverse events, N (%) | 340 (33.2) | 44 (36.1) | 296 (32.8) | 0.469 |
  Other reasons, N (%) | 293 (28.6) | 19 (15.6) | 274 (30.3) | 0.001 |
Death | ||||
 Death, N (%) | 53 (2.3) | 10 (3.7) | 43 (2.1) | 0.099 |
 Mortality duration, years, median [IQR] | 1.2 [0.36, 3.47] | 2.01 [0.25, 3.70] | 1.1 [0.36, 3.41] | 0.989 |